Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Application for Admission

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that an application has been made to the London Stock Exchange for the block listing of securities in respect of a total of 10,400,000 ordinary shares of 5 pence each ("New Ordinary Shares") to be admitted to trading on AIM. Following the admission of these Ordinary Shares, there will be no change to the Company's current issued share capital, which consists of 219,330,534 Ordinary Shares with voting rights.

The block listing application relates to New Ordinary Shares to be issued from time to time pursuant to the exercise of share options under the Company's existing schemes as follows:

In addition to the above, application has been made for 2,000,000 New Ordinary Shares has been applied for under the Employee Share Purchase Plan, previously named the Deferred Share Bonus Scheme.

An application has been made with respect to a new Block Listing for the Group Share Option Plan of 4,000,000 New Ordinary Shares.

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of 5 pence each in the capital of Advanced Medical Solutions Group plc.

It is expected that admission will become effective for the Ordinary Shares on 15 September 2025.

- End -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

-